International journal of general medicine · 2026
Association of the Remnant Cholesterol Inflammatory Index with Acute Kidney Injury After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction: A Retrospective Observational Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Qunxing, Cheng Qi, Liu Jiayu, Jiang Chunyuan, Zhang Zheng, Wang Jingxuan, Yin Delu
Аннотация
BACKGROUND: Contrast-induced acute kidney injury (CI-AKI) remains a clinically important complication after percutaneous coronary intervention (PCI), particularly in patients with ST-segment elevation myocardial infarction (STEMI). The remnant cholesterol inflammatory index (RCII), integrating remnant cholesterol (RC) and C-reactive protein (CRP), may reflect both residual lipid burden and systemic inflammatory activation. This study aimed to evaluate the association between RCII and CI-AKI in patients with STEMI undergoing PCI.
METHODS: This single-center retrospective observational study included 771 consecutive patients with STEMI who underwent primary PCI between May 2023 and May 2026. The primary outcome was in-hospital CI-AKI. Multivariable logistic regression, restricted cubic spline (RCS) analysis, receiver operating characteristic (ROC) analysis, integrated discrimination improvement (IDI), and continuous net reclassification improvement (NRI) were performed.
RESULTS: CI-AKI occurred in 85 patients (11.0%). Patients with high RCII had a significantly higher incidence of CI-AKI than those with low RCII (15.32% vs 6.74%, P<0.001). In multivariable logistic regression analysis, RCII remained independently associated with CI-AKI after adjustment for relevant covariates (adjusted odds ratio=1.026, 95% confidence interval: 1.007-1.045, P=0.007). RCS analysis demonstrated a significant nonlinear dose-response relationship between RCII and CI-AKI. The addition of RCII to the baseline clinical model resulted in significant improvements in IDI (0.027, P=0.015) and continuous NRI (0.283, P=0.007), whereas the increase in AUC was modest and not statistically significant.
CONCLUSION: Elevated RCII was independently associated with an increased risk of CI-AKI in patients with STEMI undergoing PCI. RCII may serve as a simple and readily available biomarker to assist in risk stratification.
METHODS: This single-center retrospective observational study included 771 consecutive patients with STEMI who underwent primary PCI between May 2023 and May 2026. The primary outcome was in-hospital CI-AKI. Multivariable logistic regression, restricted cubic spline (RCS) analysis, receiver operating characteristic (ROC) analysis, integrated discrimination improvement (IDI), and continuous net reclassification improvement (NRI) were performed.
RESULTS: CI-AKI occurred in 85 patients (11.0%). Patients with high RCII had a significantly higher incidence of CI-AKI than those with low RCII (15.32% vs 6.74%, P<0.001). In multivariable logistic regression analysis, RCII remained independently associated with CI-AKI after adjustment for relevant covariates (adjusted odds ratio=1.026, 95% confidence interval: 1.007-1.045, P=0.007). RCS analysis demonstrated a significant nonlinear dose-response relationship between RCII and CI-AKI. The addition of RCII to the baseline clinical model resulted in significant improvements in IDI (0.027, P=0.015) and continuous NRI (0.283, P=0.007), whereas the increase in AUC was modest and not statistically significant.
CONCLUSION: Elevated RCII was independently associated with an increased risk of CI-AKI in patients with STEMI undergoing PCI. RCII may serve as a simple and readily available biomarker to assist in risk stratification.